Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial

V. Strnad, C. Polgár, OJ. Ott, G. Hildebrandt, D. Kauer-Dorner, H. Knauerhase, T. Major, J. Łyczek, JL. Guinot, C. Gutierrez Miguelez, P. Slampa, M. Allgäuer, K. Lössl, B. Polat, R. Fietkau, A. Schlamann, A. Resch, A. Kulik, L. Arribas, P....

. 2023 ; 24 (3) : 262-272. [pub] 20230201

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003932
E-zdroje Online Plný text

NLK ProQuest Central od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2000-09-01 do Před 2 měsíci

Odkazy

PubMed 36738756
DOI 10.1016/s1470-2045(23)00018-9
Knihovny.cz E-zdroje

BACKGROUND: Several randomised, phase 3 trials have investigated the value of different techniques of accelerated partial breast irradiation (APBI) for patients with early breast cancer after breast-conserving surgery compared with whole-breast irradiation. In a phase 3 randomised trial, we evaluated whether APBI using multicatheter brachytherapy is non-inferior compared with whole-breast irradiation. Here, we present the 10-year follow-up results. METHODS: We did a randomised, phase 3, non-inferiority trial at 16 hospitals and medical centres in Austria, Czech Republic, Germany, Hungary, Poland, Spain, and Switzerland. Patients aged 40 years or older with early invasive breast cancer or ductal carcinoma in situ treated with breast-conserving surgery were centrally randomly assigned (1:1) to receive either whole-breast irradiation or APBI using multicatheter brachytherapy. Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with a supplemental boost of 10 Gy to the tumour bed, and APBI was delivered as 30·1 Gy (seven fractions) and 32·0 Gy (eight fractions) of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days. Neither patients nor investigators were masked to treatment allocation. The primary endpoint was ipsilateral local recurrence, analysed in the as-treated population; the non-inferiority margin for the recurrence rate difference (defined for 5-year results) was 3 percentage points. The trial is registered with ClinicalTrials.gov, NCT00402519; the trial is complete. FINDINGS: Between April 20, 2004, and July 30, 2009, 1328 female patients were randomly assigned to whole breast irradiation (n=673) or APBI (n=655), of whom 551 in the whole-breast irradiation group and 633 in the APBI group were eligible for analysis. At a median follow-up of 10·36 years (IQR 9·12-11·28), the 10-year local recurrence rates were 1·58% (95% CI 0·37 to 2·8) in the whole-breast irradiation group and 3·51% (1·99 to 5·03) in the APBI group. The difference in 10-year rates between the groups was 1·93% (95% CI -0·018 to 3·87; p=0·074). Adverse events were mostly grade 1 and 2, in 234 (60%) of 393 participants in the whole-breast irradiation group and 314 (67%) of 470 participants in the APBI group, at 7·5-year or 10-year follow-up, or both. Patients in the APBI group had a significantly lower incidence of treatment-related grade 3 late side-effects than those in the whole-breast irradiation group (17 [4%] of 393 for whole-breast irradiation vs seven [1%] of 470 for APBI; p=0·021; at 7·5-year or 10-year follow-up, or both). At 10 years, the most common type of grade 3 adverse event in both treatment groups was fibrosis (six [2%] of 313 patients for whole-breast irradiation and three [1%] of 375 patients for APBI, p=0·56). No grade 4 adverse events or treatment-related deaths have been observed. INTERPRETATION: Postoperative APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is a valuable alternative to whole-breast irradiation in terms of treatment efficacy and is associated with fewer late side-effects. FUNDING: German Cancer Aid, Germany.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003932
003      
CZ-PrNML
005      
20230425141004.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(23)00018-9 $2 doi
035    __
$a (PubMed)36738756
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Strnad, Vratislav $u Department of Radiation Oncology, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. Electronic address: vratislav.strnad@uk-erlangen.de
245    10
$a Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial / $c V. Strnad, C. Polgár, OJ. Ott, G. Hildebrandt, D. Kauer-Dorner, H. Knauerhase, T. Major, J. Łyczek, JL. Guinot, C. Gutierrez Miguelez, P. Slampa, M. Allgäuer, K. Lössl, B. Polat, R. Fietkau, A. Schlamann, A. Resch, A. Kulik, L. Arribas, P. Niehoff, F. Guedea, J. Dunst, C. Gall, W. Uter, Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology
520    9_
$a BACKGROUND: Several randomised, phase 3 trials have investigated the value of different techniques of accelerated partial breast irradiation (APBI) for patients with early breast cancer after breast-conserving surgery compared with whole-breast irradiation. In a phase 3 randomised trial, we evaluated whether APBI using multicatheter brachytherapy is non-inferior compared with whole-breast irradiation. Here, we present the 10-year follow-up results. METHODS: We did a randomised, phase 3, non-inferiority trial at 16 hospitals and medical centres in Austria, Czech Republic, Germany, Hungary, Poland, Spain, and Switzerland. Patients aged 40 years or older with early invasive breast cancer or ductal carcinoma in situ treated with breast-conserving surgery were centrally randomly assigned (1:1) to receive either whole-breast irradiation or APBI using multicatheter brachytherapy. Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with a supplemental boost of 10 Gy to the tumour bed, and APBI was delivered as 30·1 Gy (seven fractions) and 32·0 Gy (eight fractions) of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days. Neither patients nor investigators were masked to treatment allocation. The primary endpoint was ipsilateral local recurrence, analysed in the as-treated population; the non-inferiority margin for the recurrence rate difference (defined for 5-year results) was 3 percentage points. The trial is registered with ClinicalTrials.gov, NCT00402519; the trial is complete. FINDINGS: Between April 20, 2004, and July 30, 2009, 1328 female patients were randomly assigned to whole breast irradiation (n=673) or APBI (n=655), of whom 551 in the whole-breast irradiation group and 633 in the APBI group were eligible for analysis. At a median follow-up of 10·36 years (IQR 9·12-11·28), the 10-year local recurrence rates were 1·58% (95% CI 0·37 to 2·8) in the whole-breast irradiation group and 3·51% (1·99 to 5·03) in the APBI group. The difference in 10-year rates between the groups was 1·93% (95% CI -0·018 to 3·87; p=0·074). Adverse events were mostly grade 1 and 2, in 234 (60%) of 393 participants in the whole-breast irradiation group and 314 (67%) of 470 participants in the APBI group, at 7·5-year or 10-year follow-up, or both. Patients in the APBI group had a significantly lower incidence of treatment-related grade 3 late side-effects than those in the whole-breast irradiation group (17 [4%] of 393 for whole-breast irradiation vs seven [1%] of 470 for APBI; p=0·021; at 7·5-year or 10-year follow-up, or both). At 10 years, the most common type of grade 3 adverse event in both treatment groups was fibrosis (six [2%] of 313 patients for whole-breast irradiation and three [1%] of 375 patients for APBI, p=0·56). No grade 4 adverse events or treatment-related deaths have been observed. INTERPRETATION: Postoperative APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is a valuable alternative to whole-breast irradiation in terms of treatment efficacy and is associated with fewer late side-effects. FUNDING: German Cancer Aid, Germany.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory prsu $x patologie $7 D001943
650    12
$a brachyterapie $x škodlivé účinky $7 D001918
650    12
$a intraduktální neinfiltrující karcinom $x patologie $7 D002285
650    _2
$a segmentální mastektomie $x škodlivé účinky $7 D015412
650    _2
$a výsledek terapie $7 D016896
650    _2
$a lokální recidiva nádoru $x chirurgie $7 D009364
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Polgár, Csaba $u Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Budapest, Hungary
700    1_
$a Ott, Oliver J $u Department of Radiation Oncology, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
700    1_
$a Hildebrandt, Guido $u Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany
700    1_
$a Kauer-Dorner, Daniela $u Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria
700    1_
$a Knauerhase, Hellen $u Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany
700    1_
$a Major, Tibor $u Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Budapest, Hungary
700    1_
$a Łyczek, Jarosław $u Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skł odowskej, Warsaw, Poland; Podkarpacki Hospital Cancer Center Brzozów, Brzozów, Poland
700    1_
$a Guinot, Jose Luis $u Department of Radiation Oncology, Valencian Institute of Oncology Valencia, Valencia, Spain
700    1_
$a Gutierrez Miguelez, Cristina $u Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Allgäuer, Michael $u Department of Radiation Oncology, Hospital Barmherzige Brüder Regensburg, Regensburg, Germany
700    1_
$a Lössl, Kristina $u Department of Radiation Oncology, University Hospital Bern, Inselspital, Bern, Switzerland
700    1_
$a Polat, Bülent $u Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany
700    1_
$a Fietkau, Rainer $u Department of Radiation Oncology, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany
700    1_
$a Schlamann, Annika $u Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany
700    1_
$a Resch, Alexandra $u Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria
700    1_
$a Kulik, Anna $u Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skł odowskej, Warsaw, Poland
700    1_
$a Arribas, Leo $u Department of Radiation Oncology, Valencian Institute of Oncology Valencia, Valencia, Spain
700    1_
$a Niehoff, Peter $u Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany; Department of Radiotherapy, Sana Clinic, Offenbach, Germany
700    1_
$a Guedea, Ferran $u Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain
700    1_
$a Dunst, Jürgen $u Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany
700    1_
$a Gall, Christine $u Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Nuremberg, Germany
700    1_
$a Uter, Wolfgang $u Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Nuremberg, Germany
710    2_
$a Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 24, č. 3 (2023), s. 262-272
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36738756 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141001 $b ABA008
999    __
$a ok $b bmc $g 1924538 $s 1190141
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 3 $d 262-272 $e 20230201 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace